These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 26593311)
1. Is It Time to Start Treating Asymptomatic Hyperuricemia? Levy G; Cheetham TC Am J Kidney Dis; 2015 Dec; 66(6):933-5. PubMed ID: 26593311 [No Abstract] [Full Text] [Related]
2. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial. Sircar D; Chatterjee S; Waikhom R; Golay V; Raychaudhury A; Chatterjee S; Pandey R Am J Kidney Dis; 2015 Dec; 66(6):945-50. PubMed ID: 26233732 [TBL] [Abstract][Full Text] [Related]
3. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial. Kimura K; Hosoya T; Uchida S; Inaba M; Makino H; Maruyama S; Ito S; Yamamoto T; Tomino Y; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H; Ohtsu H; Ohashi Y; Am J Kidney Dis; 2018 Dec; 72(6):798-810. PubMed ID: 30177485 [TBL] [Abstract][Full Text] [Related]
4. Febuxostat in Hyperuricemic Patients With Advanced CKD. Lim DH; Oh JS; Ahn SM; Hong S; Kim YG; Lee CK; Choi SW; Yoo B Am J Kidney Dis; 2016 Nov; 68(5):819-821. PubMed ID: 27503183 [No Abstract] [Full Text] [Related]
5. Study of therapeutic efficacy of febuxostat in chronic kidney disease stage IIIA to stage VD. Sarvepalli PS; Fatima M; Quadri AK; Taher AR; Habeeb A; Amreen F; Parveen BN; Rajaram KG Saudi J Kidney Dis Transpl; 2018; 29(5):1050-1056. PubMed ID: 30381500 [TBL] [Abstract][Full Text] [Related]
6. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD). Sezai A; Soma M; Nakata K; Osaka S; Ishii Y; Yaoita H; Hata H; Shiono M J Cardiol; 2015 Oct; 66(4):298-303. PubMed ID: 25649025 [TBL] [Abstract][Full Text] [Related]
7. A formula predicting the effective dose of febuxostat in chronic kidney disease patients with asymptomatic hyperuricemia based on a retrospective study and a validation cohort . Aoun M; Salloum R; Dfouni A; Sleilaty G; Chelala D Clin Nephrol; 2020 Aug; 94(2):61-69. PubMed ID: 32589132 [TBL] [Abstract][Full Text] [Related]
8. Febuxostat improves endothelial function in hemodialysis patients with hyperuricemia: A randomized controlled study. Tsuruta Y; Kikuchi K; Tsuruta Y; Sasaki Y; Moriyama T; Itabashi M; Takei T; Uchida K; Akiba T; Tsuchiya K; Nitta K Hemodial Int; 2015 Oct; 19(4):514-20. PubMed ID: 25998500 [TBL] [Abstract][Full Text] [Related]
9. Febuxostat for the chronic management of hyperuricemia in patients with gout. Chinchilla SP; Urionaguena I; Perez-Ruiz F Expert Rev Clin Pharmacol; 2016; 9(5):665-73. PubMed ID: 26942273 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease . Kwak CH; Sohn M; Han N; Cho YS; Kim YS; Oh JM Int J Clin Pharmacol Ther; 2018 Jul; 56(7):321-327. PubMed ID: 29750634 [TBL] [Abstract][Full Text] [Related]
11. Effect of switching xanthine oxidoreductase inhibitor from febuxostat to topiroxostat on urinary protein excretion. Terawaki H; Hoshi H; Kazama JJ Clin Exp Nephrol; 2017 Apr; 21(2):356-357. PubMed ID: 28247173 [No Abstract] [Full Text] [Related]
12. Renal function in gout: long-term treatment effects of febuxostat. Whelton A; Macdonald PA; Zhao L; Hunt B; Gunawardhana L J Clin Rheumatol; 2011 Jan; 17(1):7-13. PubMed ID: 21169856 [TBL] [Abstract][Full Text] [Related]
13. The Effect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function. Bove M; Cicero AFG; Borghi C Curr Hypertens Rep; 2017 Oct; 19(12):95. PubMed ID: 29071435 [TBL] [Abstract][Full Text] [Related]
14. Uric Acid: The Unknown Uremic Toxin. Treviño-Becerra A Contrib Nephrol; 2018; 192():25-33. PubMed ID: 29393086 [TBL] [Abstract][Full Text] [Related]
15. Effects of Febuxostat on Oxidative Stress. Fukui T; Maruyama M; Yamauchi K; Yoshitaka S; Yasuda T; Abe Y Clin Ther; 2015 Jul; 37(7):1396-401. PubMed ID: 25913922 [TBL] [Abstract][Full Text] [Related]
16. Previous Dosage of Allopurinol Is a Strong Determinant of Febuxostat Efficacy. Koide H; Hira D; Tsujimoto M; Katsube Y; Minegaki T; Uzu T; Ikeda Y; Morita SY; Nishiguchi K; Terada T Biol Pharm Bull; 2017; 40(5):681-686. PubMed ID: 28458354 [TBL] [Abstract][Full Text] [Related]
17. Identification of chronic kidney disease patient characteristics influencing the renoprotective effects of febuxostat therapy: a retrospective follow-up study. Yamaguchi A; Harada M; Yamada Y; Hashimoto K; Kamijo Y BMC Nephrol; 2017 May; 18(1):162. PubMed ID: 28521802 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of febuxostat in patients with gout in Spain. Perez-Ruiz F; Díaz-Torné C; Carcedo D J Med Econ; 2016 Jun; 19(6):604-10. PubMed ID: 26855041 [TBL] [Abstract][Full Text] [Related]
19. Febuxostat as a renoprotective agent for treatment of hyperuricaemia: a meta-analysis of randomised controlled trials. Chewcharat A; Chen Y; Thongprayoon C; Harrison AM; Mao MA; Cheungpasitporn W Intern Med J; 2021 May; 51(5):752-762. PubMed ID: 32149437 [TBL] [Abstract][Full Text] [Related]
20. Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study. Kataoka H; Mochizuki T; Ohara M; Tsuruta Y; Iwasa N; Yoshida R; Tsuchiya K; Nitta K; Kimura K; Hosoya T; Sci Rep; 2022 Mar; 12(1):3784. PubMed ID: 35260678 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]